Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases-Reference-Cited by-同舟云学术

Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases

Published:2014-10-01 Issue:28 Volume:32 Page:3204-3205
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Adams Sylvia¹,Novik Yelena¹,Oratz Ruth¹,Axelrod Deborah¹,Speyer James¹,Tiersten Amy²,Goldberg Judith D.¹,Bhardwaj Nina²,Unutmaz Derya¹,Demaria Sandra¹,Formenti Silvia¹

Affiliation:

1. New York University School of Medicine, New York, NY

2. Mount Sinai School of Medicine, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Reference5 articles.

1. Imiquimod in the Treatment of Breast Cancer Skin Metastasis

2. Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

3. Topical Imiquimod to Treat Recurrent Breast Cancer

4. Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer

5. Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Charting roadmaps towards novel and safe synergistic immunotherapy combinations;Nature Cancer;2022-06-28

2. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors;Journal for ImmunoTherapy of Cancer;2020-10

3. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes;European Journal of Medicinal Chemistry;2020-05

4. Imiquimod Inhibits Proliferation of Serous Epithelial Ovarian Cancer Cells In Vitro: A Preliminary Study;Indian Journal of Gynecologic Oncology;2020-04-15

5. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies;Journal for ImmunoTherapy of Cancer;2019-09-11